RETARGETING THE ANTIBIOTIC AZITHROMYCIN AS AN ANTIMALARIAL WITH DUAL MODALITY
Grant number: 1143974 | Funding period: 2018 - 2021
Malaria parasites resistant to first-line treatments continue to spread in South East Asia. New drugs need to be developed urgently to ensure alternative treatment strategies are available. We will retarget the safe and widely used antibiotic azithromycin as an antimalarial with dual modalities against parasite invasion and growth inside the host red blood cell. This strategy has significant potential to increase drug efficacy while reducing the chances for the development of resistance.